World Health Organization

Department of Immunization, Vaccines and Biologicals (IVB)

SAGE

meeting

Strategic Advisory Group of Experts on Immunization
3-6 October 2022

Hybrid meeting, WHO
Geneva, Switzerland

SEE page 2 for instructions about how to open and use this interactive pdf

Back to table of contents

This document can be found online after the meeting at the following link: https://www.who.int/news-room/events/detail/2022/10/03/default-calendar/sage_meeting_october_2022

This interactive pdf contains all background documents for the corresponding meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization.

To function correctly, this document needs to be downloaded and opened with Acrobat Reader (please download software if necessary). DO NOT OPEN IT in a web browser as it will not allow to access embedded documents.

Navigation is done via the interactive table of content page. Each session landing page contains links to the executive summary and all background documents (tagged as either essential or additional). All session documents open as new tabs in the Adobe reader (pdf attachments).

Tip: Avoid opening more than 6-8 tabs at a time to preserve navigability.

Notes:
(1) This document functions only in a limited mode on hand-held devices. See “How to Guide”.
(2) Presentations from the meeting will be made available once the meeting has concluded at the above link and through an additional interactive PDF.

Back to table of contents

TABLE OF CONTENTS

AGENDA	
SAGE ADMINISTRATION AND GENERAL DOCUMENTS	
A	Terms of reference
B	SAGE members
C	Declaration of interests form for WHO experts
D	Current SAGE working groups
E	"How to" guide for interactive SAGE yellow book
F	Provisional list of meeting participants: see webpage
SESSIONS (with access to background materials)	
1	Global reports
2	IA2030 and Regional updates
3	Orthopox/Monkeypox
4	RSV
5	Polio
6	COVID-19
7	Ebola

Back to table of contents

World Health Organization

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
3–6 October 2022
Hybrid Meeting (CET)
Draft Agenda

Day 1: Monday, 3 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Preparation of the sessions of the day.	1h
10:30	Break	Break	15 min.
10:45	Opening and welcome – introduction of participants K. O'BRIEN, IVB Director WHO. A. CRAVIOTO, SAGE chair J. HOMBACH, SAGE secretariat WHO.	Opening of the Plenary Meeting by DG WHO (tbc)	15 min.
11:00	Global Reports – Session 1 Report from the Director of IVB. K. O'BRIEN, WHO. 30 min. Update from Gavi. S. BERKLEY, GAVI. 10 min. Discussion. 20 min	FOR INFORMATION	1h.
12:00	IA2030 and Regional updates – Session 2 Brief introduction of the session and objectives. F. OLAYINKA and N. MACDONALD, SAGE members. 5 min Overview of IA2030 implementation progress. A.M. ROPERO. WHO. 15 min Overview of IA2030 Technical Progress Report analyses. J. GREVENDONK. WHO. 20 min. Discussion. 10 min	FOR RECOMMENDATION Brief update on IA2030 implementation progress, in line with the IA2030 Framework for Action. Present the IA2030 Technical Progress Report for 2022, including analyses of global and regional progress towards IA2030 impact goal targets and strategic priority objectives.	50 min (3h20 in total)
12:50	Break	Break	45 min.
13:35	IA2030 and Regional updates – Session 2 (continued) Reports from the Regions. WHO. 1h30 AFRO and EMRO, 10 min each + 10 min Q&A EURO and PAHO, 10 min each + 10 min Q&A WPRO and SEARO, 10 min each + 10 min Q&A Overview of IA2030 Partnership Working Group recommendations for consideration by SAGE. E. MAST. IA2030 M&E WG chair. 20 min. Discussion. 40 min.	FOR RECOMMENDATION Present considerations for technical and policy-related recommendations to address corrective actions needed to address widening immunization gaps. Receive decisions from SAGE on these proposed recommendations developed collectively across the IA2030 partnership.	2h30 (3h20 in total)
16:05	End of the day		

Back to table of contents

Day 2: Tuesday 4 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Development of recommendations of day 1. Preparation of the sessions of the day. Other important discussion items.	1h30
11:00	Break	Break	15 min.
11:15	Orthopox/Monkeypox – Session 3 Introduction of session, K. NEUZIL. SAGE member and Working Group Chair. 5 min. Update on Monkeypox epidemiology. TBC. 10 min. WHO global strategy on monkeypox vaccination. T. CERNUSCHI, WHO. Q&A. 15 min. Evidence on vaccine safety, immunogenicity, efficacy and safety of the vaccines currently used in the outbreak response. J. VAN HOLTEN. WHO. Q&A. 20 min. Draft recommendations. K. NEUZIL. SAGE member and Working Group Chair. 20 min. Q&A and discussion. 50 min.	FOR RECOMMENDATION Provide a brief update on Monkeypox epidemiology and ongoing vaccine interventions, including vaccine access/supply Present and discuss WHO's strategy on Monkeypox vaccination in context of the Public Health emergency of international concern (PHEIC) Recommend any update needed to WHO's interim guidance on Monkeypox vaccination based on rapid evidence reviews and early experience from vaccination, with specific consideration of: – Post exposure vaccination – Pre-exposure vaccination target groups – Vaccination strategies for special populations – Vaccine choices	2h
13:15	Break	Break	1h.
14:15	RSV – Session 4 Introduction of session. K. NEUZIL. SAGE member. 5 min. New RSV global burden of disease estimates, results from community mortality studies and RSV surveillance under GISRS. D. FEIKIN. WHO. 15 min. Pipeline of late stage candidates and timelines for mAbs and maternal vaccines. Clinical trial results for nirsevimab phase 3 and phase 2b Pfizer maternal vaccine. E. SPARROW. WHO. 15 min. Summary of TAG discussion on additional data needs from LMICs. H. ZAR. RSV TAG chair. 25 min. Discussion. 30 min.	FOR DISCUSSION SAGE input on what additional information (if any) would be needed for a policy recommendation for the two lead candidates, nirsevimab and the Pfizer maternal vaccine data needs for policy (vaccines)	1h30
15:45	End of the day		

Back to table of contents

Day 3: Wednesday 5 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Development of recommendations of day 2. Preparation of the sessions of the day. Other important discussion items.	1h30
11:00	Break	Break	15 min.
11:15	Polio – Session 5 Session overview. I. JANI. SAGE member. 5 min. Update from the Global Polio Eradication Initiative. A. O'LEARY. WHO. 20 min. Questions: 20 min. IPV as an option for VDPV outbreak response in IPV-only using countries. TBD. WHO, 15 min. Questions: 5 min Role of older children in poliovirus transmission. O. MACH. WHO. 10 minutes. Questions: 5 min. Report from SAGE Polio Working Group including update on novel OPVs. I. JANI, SAGE Member. 15 min. Discussion: 10 min.	FOR RECOMMENDATION SAGE will be informed on the current status of the polio eradication programme and of the implementation of the new polio eradication strategy. SAGE will be updated on the use and clinical development of novel OPVs. SAGE will be asked to review and consider for endorsement: • WG's recommendation on "Options for VDPV outbreak response in IPV-only using countries" • WG's recommendation on criteria for expanding age group in poliovirus outbreak response vaccination campaigns	1h45
13:00	Break	Break	45 min.
13:45	COVID-19 vaccines – Session 6 *Variant-containing vaccines* Waning protection against new variants both from vaccine and infection-induced immunity (20 min) Immunogenicity data from variant-containing vaccines (20 min) Discussion (30 min) Policy recommendation (20 min) *Corbevax (Biological E) Covid-19 vaccine review* Evidence review. 30 min Evidence to recommendation tables. 15 min Policy recommendations and discussion. 45 min	FOR RECOMMENDATION To formulate policy recommendations for the use of variant-containing vaccines To formulate policy recommendations for use of Corbevax COVID-19 vaccine, once EUL is obtained	3h
16:45	End of the day		

Back to table of contents

Day 4: Thursday 6 October 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
9:30	Closed SAGE meeting	Development of recommendations of day 3. Preparation of the sessions of the day. Other important discussion items.	1h30
11:00	Break	Break	15 min.
11:15	Ebola – Session 7 Introduction of the session and questions for SAGE consideration. E. MOHSNI Ebola WG chair. SAGE member. 5 min. Epidemiology of Ebola – overview of recent outbreaks in DRC. JJ MUYEMBE. 10 min. Understanding Ebola virus persistence in immune privileged sites and duration of protection after natural infection. M. CAROLL. 10 min. Ring vaccination in response to outbreaks – achievements and lessons learned. A. DIALLO and A. TOURE. 10 min. Overview of Ebola vaccines immunogenicity and duration of antibody titres. WHO. 10 min. Efficacy and effectiveness of rVSV ZEBOV GP vaccine. R. PETO. 10 min. Current availability of doses and production capacity. Gavi/UNICEF. 5 min. Proposed recommendations for SAGE consideration and discussion. 30 min.	FOR RECOMMENDATION To review the current SAGE recommendations for use of rVSV ZEBOV GP and Ad26 + MVA Ebola vaccines and discuss relevant adjustments to: 1) Response to outbreaks: Target population (including special populations); Delivery strategy(ies); Duration of protection and need for booster doses 2) Preventive vaccination (in the absence of an outbreak): Target population; Delivery strategy(ies); Duration of protection and need for booster doses	2h
13:15	End of SAGE Plenary meeting		
13:15	Break	Break	1h
14:15	Closed SAGE session	Meeting wrap up.	2h
16:15	End of final closed meeting		

SESSION 1: GLOBAL REPORTS

EXECUTIVE SUMMARY	
1.0	Executive summary: Global and regional reports

BACKGROUND DOCUMENTS (essential)	
-	None

BACKGROUND DOCUMENTS (additional)	
1.1	Report from the first joint meeting (virtual) of WHO Global Advisory Committee on Vaccine Safety and WHO Advisory Committee on Safety of Medicinal Products, 14–16 June 2022
1.2	WHO Expert Committee on Biological Standardization Seventy-fifth report
1.3	Meeting of the Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC), March 2022. Report
1.4	13th meeting of the WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR ITAG) New Delhi, India, 17-19 August 2022. Agenda.
1.5	31st meeting of the technical advisory group on immunization and vaccine-preventable diseases in the western pacific region. 17 June 2022. Agenda

SESSION 2: IA2030 AND REGIONAL UPDATES

EXECUTIVE SUMMARY	
2.0	Executive Summary: IA2030 and regional updates

BACKGROUND DOCUMENTS (essential)	
2.1	IA2030 Technical Progress Report (TPR) for 2022, including Considerations for IA2030 Recommendations by SAGE

BACKGROUND DOCUMENTS (additional)	
-	-

SESSION 3: ORTHOPOX/MONKEYPOX

EXECUTIVE SUMMARY	
3.0	Executive Summary: monkeypox

BACKGROUND DOCUMENTS (essential)	
3.1	Vaccines and immunization for monkeypox. Interim guidance. 24 August 2022
3.2	Multi-country outbreak of monkeypox. External Situation Report 5, published 7 September 2022
3.3	Systematic review on monkeypox vaccines

BACKGROUND DOCUMENTS (additional)	
3.3	List of other web background information on monkeypox

Please note that due to the rapidly evolving situation, that additional material for the monkeypox vaccine session will be shared separately at short notice.

SESSION 4: RSV

EXECUTIVE SUMMARY	
4.0	Executive Summary: RSV

BACKGROUND DOCUMENTS (essential)	
4.1	Global Burden study 2022
4.2	Community mortality studies (intro paper to special issue)
4.3	Phase 3 trial results of nirsevmab
4.4	Phase 2b trial results of Pfizer's maternal vaccines

BACKGROUND DOCUMENTS (additional)	
4.5	Phase 3 trial of nirsevmab, supplementary files
4.6	Phase 2b trial results of nirsevimab

SESSION 5: POLIO

EXECUTIVE SUMMARY	
5.0	Executive Summary: Polio

BACKGROUND DOCUMENTS (essential)	
5.1	Report from polio SAGE WG meeting
5.2	Report from the meeting of GACVS sub-committee on nOPV2 safety

BACKGROUND DOCUMENTS (additional)	
-	-

SESSION 6: COVID-19 VACCINES

EXECUTIVE SUMMARY	
6.0	Executive Summary: COVID-19 Vaccines

BACKGROUND DOCUMENTS (essential)	
-	-

BACKGROUND DOCUMENTS (additional)	
-	-

Please note that due to the rapidly evolving situation, material for the Covid-19 vaccine session will be shared separately at short notice.

SESSION 7: EBOLA

EXECUTIVE SUMMARY	
7.0	Executive Summary: Ebola

BACKGROUND DOCUMENTS (essential)	
-	-

BACKGROUND DOCUMENTS (additional)	
-	-

Please note that Ebola session related material was not available at the time of finalisation of the Yellow book and will be shared separately at short notice.